Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis
Alexandra Serris(Délégation Paris 5), Fanny Lanternier(Hôpital Necker-Enfants Malades), Vincent Bedarida(Hôpital Fernand-Widal), Jean‐Herlé Raphalen(Université Sorbonne Paris Nord), S. Poirée(Hôpital Necker-Enfants Malades), Olivier Lambotte(Inserm), Marianne Gazzano(Assistance Publique – Hôpitaux de Paris), Amani Ouedrani(Hôpital Necker-Enfants Malades), Claire Rouzaud(Hôpital Necker-Enfants Malades), Guillaume Martin‐Blondel(Centre Hospitalier Universitaire de Toulouse), Marie‐Elisabeth Bougnoux(Hôpital Necker-Enfants Malades), Fabrice Uhel(Hôpital Louis-Mourier)
Cited by 35
Related Papers
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
|The Lancet Infectious Diseases|2019|1.7k
Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study
|Radiology|2020|471
Deep Dermatophytosis and Inherited CARD9 Deficiency
|New England Journal of Medicine|2013|403
A Pre-Hospital Extracorporeal Cardio Pulmonary Resuscitation (ECPR) strategy for treatment of refractory out hospital cardiac arrest: An observational study and propensity analysis
|Resuscitation|2017|373
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
|Nature Medicine|2021|367